Education
About Us
Working with TipRanks
Follow Us
Transgene SA (GB:0OCQ)
LSE:0OCQ
0OCQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.56 - €1.17
Previous CloseN/A
Volume384.00
Average Volume (3M)176.00
Market Cap
€109.89M
Enterprise Value€87.91M
Total Cash (Recent Filing)€16.67M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Sep 16, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding132,735,080
10 Day Avg. Volume122
30 Day Avg. Volume176
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)6.86
Price to Sales (P/S)0.00
P/FCF Ratio-3.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
0OCQ FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest share price was €0.56 and its highest was €1.17 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €109.89M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 16, 2025 which is in 51 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Transgene SA dividends here
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 132,735,080 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in GB:0OCQ
Company Description
Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Technical Analysis
Genfit
―
Innate Pharma SA
―
DBV Technologies
―
Nanobiotix
―
OSE Immunotherapeutics SA
―